Endurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age20+
SponsorMedtronic Cardiovascular

About this trial

The purpose of this trial is to generate clinical evidence related to key performance outcomes of Endurant II/IIs Stent Graft Systems verses Gore Excluder / Excluder Conformable AAA Endoprosthesis in subjects with Abdominal Aortic Aneurysms. Subjects are randomized and imaging collected at all follow-up time points to assess the primary endpoint.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Subject and the treating physician agree that the subject will return for all required follow up visits

Subject or legal representative or consultee, as applicable, has consented for trial participation and signed the Informed Consent approved by the sponsor and by the Ethics Committee/Institutional Review Board

Subject has an aneurysm diameter of ≥ 5 cm (if woman) ≥ 5.5 cm (if man) or as stated otherwise in regional addenda.

Subject's AAA anatomy is appropriate for both Medtronic Endurant II/IIs Stent Graft System and Gore Excluder/Excluder Conformable AAA Endoprosthesis as per assessment of both treating physician and Core Lab in accordance with the overlapping commercially available IFUs per applicable region.

Disqualifiers

Subject is participating in an investigational drug or device study which may bias or interfere with the endpoints and follow-up of this trial

Subject has an estimated life expectancy of ≤ 3 years as judged by the investigator

Suprarenal/pararenal/juxtarenal

Isolated ilio-femoral

Trial design

Design model

Parallel

Treatments tested in this trial

  • Medtronic Endurant II or Endurant IIs Stent Graft System

    Device

    EVAR treatment with Medtronic Endurant II/IIs Stent Graft System

  • Gore Excluder or Gore/ Excluder Conformable AAA Endoprosthesis

    Device

    EVAR treatment with Excluder / Excluder Conformable Stent Graft System

Treatment groups

600 Participants
are divided into 2 treatment groups
Group A: Medtronic Endurant II/IIsExperimental treatment 1 intervention
Group B: Gore Excluder / Excluder ConformableExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Sac Regression

Proportion of patients with sac regression at 1 year, defined in accordance with SVS guidelines as the reduction in maximum diameter by \>= 5 mm when compared to the first CT imaging study obtained within 90 days after index procedure.

Time frame
12 months

Secondary outcomes

1

Aneurysm sac change by diameter as a continuous variable

Time frame
12 months and annually to 5 years
2

Aneurysm sac change by volume incidence rate

Time frame
12 months and annually to 5 years
3

Type II endoleak incidence rate

Time frame
30 days, 12 months and annually to 5 years
4

Type I endoleak incidence rate

Time frame
30 days,12 months and annually to 5 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.